Please assess the completion status of the following clinical trial:

Trial Title: Timed Release Tablet Prednisone in Polymyalgia Rheumatica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PMR by standard criteria. The Bird criteria will be used. 3 or more features are required to make the diagnosis.~  * Bilateral shoulder pain/stiffness~ * Duration of symptoms \<2/52~ * Initial ESR \>40 mm/h~ * Stiffness \>1 h~ * Age \>65 years~ * Depression and/or weight loss~ * Bilateral upper arm tenderness~* Are over 50 but less than 85 years old.~* No or stable NSAID or analgesic therapy for at least 7 days.~* Currently active disease defined by a CRP at least 10mg/L, ESR at least 29mm in one hour or PV \>1.72~Exclusion Criteria:~* Currently on oral glucocorticoid treatment or taken within 2 months~* Parenteral glucocorticoid treatment with the last 2 months~* Pregnancy and lactation~* Inflammatory diseases such as inflammatory bowel disease, colitis, asthma~* Co-existent giant cell arteritis~* Other auto-immune diseases~* Cancer~* Infections, treatment with antibiotics within the past 6 weeks~* Significant renal disease (creatinine \>150 μmol/L)~* Significant hepatic impairment~* Participation in a clinical trial within the past 30 days~* Working shift employee~* Jet lag

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Timed Release Tablet Prednisone (Type: EXPERIMENTAL): 12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
- Standard Prednisolone (Type: ACTIVE_COMPARATOR): 12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).